Skip to main content

Table 1 Baseline characteristics in diabetic patients with NAFLD

From: Effect of omega-3 supplementation on cardiometabolic indices in diabetic patients with non-alcoholic fatty liver disease: a randomized controlled trial

  Omega-3 (n = 30) Placebo (n = 30)
Age*, y 48.6 ± 7.6 48.8 ± 8.7
Gender*
 Male, n (%) 9 (30) 6 (20)
 Female, n (%) 21 (70) 24 (80)
Energy intake, kcal/d 1585.1 ± 572.8 1200.2 ± 295.5
MET, (h/d) 28.1 ± 4.2 27.7 ± 3.9
Height*, cm 160.4 ± 8.9 160.5 ± 8.2
Weight*, kg 78.0 ± 10.5 77.1 ± 12.5
BMI*, kg/m2 30.2 ± 3.6 29.8 ± 4.2
WC*, cm 106.7 ± 9.1 104.2 ± 9.8
HDL-c*, mg/dL 45.3 ± 8.9 46.5 ± 8.03
LDL-c*, mg/dL 95.9 ± 30.0 92.2 ± 22.2
TG*, mg/dL 151.6 ± 57.5 138.4 ± 51.8
TC*, mg/dL 166.0 ± 41.1 159.9 ± 29.3
AIP* 0.49 ± 0.22 0.44 ± 0.19
Castelli risk index I* 3.63 ± 0.9 3.41 ± 0.7
Castelli risk index II* 2.11 ± 0.6 1.97 ± 0.5
AC* 2.63 ± 0.9 2.41 ± 0.7
  1. P values are computed by independent t-test and data are expressed as mean ± standard deviation (SD), while for Gender is computed by chi-square test and data are expressed as number (percent)
  2. *: No significant difference was found between two groups at the baseline, except for energy intake (P = 0.002)
  3. NAFLD Non-alcoholic fatty liver disease, MET-h Metabolic equivalent task, BMI Body mass index, WC Waist circumference, HDL-c High density lipoprotein-cholesterol, TG Triglyceride, TC Total cholesterol, AIP Atherogenic index of plasma, AC Atherogenic coefficient